Goldman Sachs Initiates Coverage of Soleno Therapeutics (SLNO) With a Buy Rating

Core Viewpoint - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is highlighted as a promising healthcare stock with significant upside potential, particularly following Goldman Sachs' initiation of coverage with a Buy rating and a price target of $125 [1]. Group 1: Company Overview - Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases, specifically targeting neurobehavioral and metabolic disorders [3]. - The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR), is an oral tablet designed to treat Prader-Willi Syndrome (PWS) [3]. Group 2: Recent Developments - Goldman Sachs anticipates that Soleno Therapeutics' Vykat XR will become a foundational treatment for Prader-Willi syndrome, with expectations for the drug to evolve into a blockbuster franchise [2]. - The recent pullback in the stock price is viewed as an attractive entry point for investors looking to capitalize on the company's potential [2].